Small Cell Lung Cancer

Restricted access
  • 1

    Oberg K, Hellman P, Kwekkeboom D, Jelic S. Neuroendocrine bronchial and thymic tumours: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v220-222.

    • Search Google Scholar
    • Export Citation
  • 2

    Govindan R, Page N, Morgensztern D. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol 2006;24:4539-4544.

    • Search Google Scholar
    • Export Citation
  • 3

    Navada S, Lai P, Schwartz A, Kalemkerian G. Temporal trends in small cell lung cancer: analysis of the national Surveillance, Epidemiology, and End-Results (SEER) database [abstract]. J Clin Oncol 2006;24(Suppl 18):Abstract 7082.

    • Search Google Scholar
    • Export Citation
  • 4

    Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.

    • Search Google Scholar
    • Export Citation
  • 5

    Murray N, Turrisi AT III. A review of first-line treatment for small-cell lung cancer. J Thorac Oncol 2006;1:270-278.

  • 6

    Hann CL, Rudin CM. Management of small-cell lung cancer: incremental changes but hope for the future. Oncology (Williston Park) 2008;22:1486-1492.

    • Search Google Scholar
    • Export Citation
  • 7

    Kalemkerian GP. Advances in the treatment of small-cell lung cancer. Semin Respir Crit Care Med 2011;32:94-101.

  • 8

    Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 2010;15:187-195.

  • 9

    Johnson BE, Janne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am 2004;18:309-322.

    • Search Google Scholar
    • Export Citation
  • 10

    Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J 2010;35:202-215.

    • Search Google Scholar
    • Export Citation
  • 11

    Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance Epidemiology and End Results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010;5:215-219.

    • Search Google Scholar
    • Export Citation
  • 12

    Videtic GMM, Stitt LW, Dar AR. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-1549.

    • Search Google Scholar
    • Export Citation
  • 13

    Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:3-8.

  • 14

    Brenner B, Tang LH, Klimstra DS, Kelsen DP. Small-cell carcinomas of the gastrointestinal tract: a review. J Clin Oncol 2004;22:2730-2739.

  • 15

    Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. Cancer 1997;79:1729-1736.

  • 16

    Remick SC, Ruckdeschel JC. Extrapulmonary and pulmonary small-cell carcinoma: tumor biology, therapy, and outcome. Med Pediatr Oncol 1992;20:89-99.

    • Search Google Scholar
    • Export Citation
  • 17

    Johnson BE, Whang-Peng J, Naylor SL. Retention of chromosome 3 in extrapulmonary small cell cancer shown by molecular and cytogenetic studies. J Natl Cancer Inst 1989;81:1223-1228.

    • Search Google Scholar
    • Export Citation
  • 18

    Guinee DG Jr, Fishback NF, Koss MN. The spectrum of immunohistochemical staining of small-cell lung carcinoma in specimens from transbronchial and open-lung biopsies. Am J Clin Pathol 1994;102:406-414.

    • Search Google Scholar
    • Export Citation
  • 19

    Gustafsson BI, Kidd M, Chan A. Bronchopulmonary neuroendocrine tumors. Cancer 2008;113:5-21.

  • 20

    Renshaw AA, Haja J, Lozano RL, Wilbur DC. Distinguishing carcinoid tumor from small cell carcinoma of the lung: correlating cytologic features and performance in the College of American Pathologists Non-Gynecologic Cytology Program. Arch Pathol Lab Med 2005;129:614-618.

    • Search Google Scholar
    • Export Citation
  • 21

    Lung cancer trial results show mortality benefit with low-dose CT. National Cancer Institute Web site. Available at: http://www.cancer.gov/newscenter/pressreleases/2010/NLSTresultsRelease. Accessed September 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 22

    Cuffe S, Moua T, Summerfield R. Characteristics and outcomes of small cell lung cancer patients diagnosed during two lung cancer computed tomographic screening programs in heavy smokers. J Thorac Oncol 2011;6:818-822.

    • Search Google Scholar
    • Export Citation
  • 23

    Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer 2011;10:33.

    • Search Google Scholar
    • Export Citation
  • 24

    Marchioli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin N Am 1997;7:65-80.

  • 25

    Titulaer MJ, Wirtz PW, Willems LN. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol 2008;26:4276-4281.

    • Search Google Scholar
    • Export Citation
  • 26

    Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD. Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 1996;40:739-749.

    • Search Google Scholar
    • Export Citation
  • 27

    Graus F, Keime-Guibert F, Rene R. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-1148.

  • 28

    Delisle L, Boyer MJ, Warr D. Ectopic corticotropin syndrome and small-cell carcinoma of the lung. Clinical features, outcome, and complications. Arch Intern Med 1993;153:746-752.

    • Search Google Scholar
    • Export Citation
  • 29

    Johnson BE, Chute JP, Rushin J. A prospective study of patients with lung cancer and hyponatremia of malignancy. Am J Respir Crit Care Med 1997;156:1669-1678.

    • Search Google Scholar
    • Export Citation
  • 30

    Micke P, Faldum A, Metz T. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits limited disease? Lung Cancer 2002;37:271-276.

    • Search Google Scholar
    • Export Citation
  • 31

    Shepherd FA, Crowley J, Van Houtte P. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-1077.

    • Search Google Scholar
    • Export Citation
  • 32

    Ignatius Ou SH, Zell JA. The applicability of the proposed IASLC staging revisions to small cell lung cancer (SCLC) with comparison to the current UICC 6th TNM Edition. J Thorac Oncol 2009;4:300-310.

    • Search Google Scholar
    • Export Citation
  • 33

    Vallieres E, Shepherd FA, Crowley J. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:1049-1059.

    • Search Google Scholar
    • Export Citation
  • 34

    Edge SB, Byrd DR, Compton CC. AJCC Cancer Staging Manual, 7th ed. New York, NY: Springer; 2010.

  • 35

    Goldstraw P, Crowley J, Chansky K. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-714.

    • Search Google Scholar
    • Export Citation
  • 36

    Podoloff DA, Ball DW, Ben-Josef E. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 2009;7(Suppl 2):S1-26.

    • Search Google Scholar
    • Export Citation
  • 37

    Bradley JD, Dehdashti F, Mintun MA. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:3248-3254.

    • Search Google Scholar
    • Export Citation
  • 38

    Kut V, Spies W, Spies S. Staging and monitoring of small cell lung cancer using [18F]fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET). Am J Clin Oncol 2007;30:45-50.

    • Search Google Scholar
    • Export Citation
  • 39

    Azad A, Chionh F, Scott AM. High impact of 18F-FDG-PET on management and prognostic stratification of newly diagnosed small cell lung cancer. Mol Imaging Biol 2010;12:443-451.

    • Search Google Scholar
    • Export Citation
  • 40

    Fischer BM, Mortensen J, Langer SW. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol 2007;18:338-345.

    • Search Google Scholar
    • Export Citation
  • 41

    Brink I, Schumacher T, Mix M. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging 2004;31:1614-1620.

    • Search Google Scholar
    • Export Citation
  • 42

    Kamel EM, Zwahlen D, Wyss MT. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-1917.

    • Search Google Scholar
    • Export Citation
  • 43

    Vinjamuri M, Craig M, Campbell-Fontaine A. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer 2008;9:30-34.

    • Search Google Scholar
    • Export Citation
  • 44

    Rintoul RC, Tournoy KG, El Daly H. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes- an international multi-centre experience. J Thorac Oncol 2009;4:44-48.

    • Search Google Scholar
    • Export Citation
  • 45

    Medford AR, Bennett JA, Free CM, Agrawal S. Mediastinal staging procedures in lung cancer: EBUS, TBNA and mediastinoscopy. Curr Opin Pulm Med 2009;15:334-342.

    • Search Google Scholar
    • Export Citation
  • 46

    Foster NR, Mandrekar SJ, Schild SE. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009;115:2721-2731.

    • Search Google Scholar
    • Export Citation
  • 47

    Albain KS, Crowley JJ, LeBlanc M, Livingston RB. Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base. J Clin Oncol 1990;8:1563-1574.

    • Search Google Scholar
    • Export Citation
  • 48

    Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 2000;28:173-185.

  • 49

    Pignon JP, Arriagada R, Ihde DC. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992;327:1618-1624.

  • 50

    Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 1992;10:890-895.

    • Search Google Scholar
    • Export Citation
  • 51

    Postmus PE, Haaxma-Reiche H, Gregor A. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998;46:29-32.

    • Search Google Scholar
    • Export Citation
  • 52

    Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004;49:119-133.

  • 53

    Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-392.

  • 54

    Johnson BE. Management of small cell lung cancer. Clin Chest Med 2002;23:225-239.

  • 55

    Evans WK, Shepherd FA, Feld R. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-1477.

  • 56

    Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-1396.

  • 57

    Sundstrom S, Bremnes RM, Kaasa S. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 2002;20:4665-4672.

    • Search Google Scholar
    • Export Citation
  • 58

    Saito H, Takada Y, Ichinose Y. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 2006;24:5247-5252.

    • Search Google Scholar
    • Export Citation
  • 59

    Takada M, Fukuoka M, Kawahara M. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 2002;20:3054-3060.

    • Search Google Scholar
    • Export Citation
  • 60

    Bunn PA Jr, Crowley J, Kelly K. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 1995;13:1632-1641.

    • Search Google Scholar
    • Export Citation
  • 61

    Bishop JF, Raghavan D, Stuart-Harris R. Carboplatin (CBDCA, JM-8) and VP-16-213 in previously untreated patients with small-cell lung cancer. J Clin Oncol 1987;5:1574-1578.

    • Search Google Scholar
    • Export Citation
  • 62

    Skarlos DV, Samantas E, Briassoulis E. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 2001;12:1231-1238.

    • Search Google Scholar
    • Export Citation
  • 63

    Skarlos DV, Samantas E, Kosmidis P. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 1994;5:601-607.

    • Search Google Scholar
    • Export Citation
  • 64

    Okamoto H, Watanabe K, Kunikane H. Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702. Br J Cancer 2007;97:162-169.

    • Search Google Scholar
    • Export Citation
  • 65

    Noda K, Nishiwaki Y, Kawahara M. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346:85-91.

    • Search Google Scholar
    • Export Citation
  • 66

    Lara PN Jr., Natale R, Crowley J. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.

    • Search Google Scholar
    • Export Citation
  • 67

    Hanna N, Bunn PA Jr, Langer C. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.

    • Search Google Scholar
    • Export Citation
  • 68

    Schmittel A, Fischer von Weikersthal L, Sebastian M. A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 2006;17:663-667.

    • Search Google Scholar
    • Export Citation
  • 69

    Hermes A, Bergman B, Bremnes R. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol 2008;26:4261-4267.

    • Search Google Scholar
    • Export Citation
  • 70

    Lima JP, dos Santos LV, Sasse EC. Camptothecins compared with etoposide in combination with platinum analog in extensive stage small cell lung cancer: systematic review with meta-analysis. J Thorac Oncol 2010;5:1986-1993.

    • Search Google Scholar
    • Export Citation
  • 71

    Chute JP, Chen T, Feigal E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.

    • Search Google Scholar
    • Export Citation
  • 72

    Niho S, Kubota K, Yoh K. Clinical outcome of chemoradiation therapy in patients with limited-disease small cell lung cancer with ipsilateral pleural effusion. J Thorac Oncol 2008;3:723-727.

    • Search Google Scholar
    • Export Citation
  • 73

    Niho S, Kubota K, Yoh K. Chemoradiation therapy in patients (pts) with small cell lung cancer (SCLC) with pericardial effusion but no distant metastasis [abstract]. J Clin Oncol 2009;27(Suppl 15):Abstract 7555.

    • Search Google Scholar
    • Export Citation
  • 74

    Loehrer PJ Sr, Ansari R, Gonin R. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995;13:2594-2599.

    • Search Google Scholar
    • Export Citation
  • 75

    Pujol JL, Daures JP, Riviere A. Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study. J Natl Cancer Inst 2001;93:300-308.

    • Search Google Scholar
    • Export Citation
  • 76

    Miyamoto H, Nakabayashi T, Isobe H. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992;49:431-435.

    • Search Google Scholar
    • Export Citation
  • 77

    Niell HB, Herndon JE II, Miller AA. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol 2005;23:3752-3759.

    • Search Google Scholar
    • Export Citation
  • 78

    Schiller JH, Adak S, Cella D. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593—a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:2114-2122.

    • Search Google Scholar
    • Export Citation
  • 79

    Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.

    • Search Google Scholar
    • Export Citation
  • 80

    Fukuoka M, Furuse K, Saijo N. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 1991;83:855-861.

    • Search Google Scholar
    • Export Citation
  • 81

    Roth BJ, Johnson DH, Einhorn LH. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1992;10:282-291.

    • Search Google Scholar
    • Export Citation
  • 82

    Miles DW, Earl HM, Souhami RL. Intensive weekly chemotherapy for good-prognosis patients with small-cell lung cancer. J Clin Oncol 1991;9:280-285.

    • Search Google Scholar
    • Export Citation
  • 83.

    Murray N, Gelmon K, Shah A. Potential for long-term survival in extensive stage small-cell lung cancer (ESCLC) with CODE chemotherapy and radiotherapy [abstract]. Lung Cancer 1994;11(Suppl 1):99. Abstract 377.

    • Search Google Scholar
    • Export Citation
  • 84

    Sculier JP, Paesmans M, Bureau G. Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party. J Clin Oncol 1993;11:1858-1865.

    • Search Google Scholar
    • Export Citation
  • 85

    Souhami RL, Rudd R, Ruiz de Elvira MC. Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial. J Clin Oncol 1994;12:1806-1813.

    • Search Google Scholar
    • Export Citation
  • 86

    Fukuoka M, Masuda N, Negoro S. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer 1997;75:306-309.

    • Search Google Scholar
    • Export Citation
  • 87

    Murray N, Livingston RB, Shepherd FA. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 1999;17:2300-2308.

    • Search Google Scholar
    • Export Citation
  • 88

    Teicher BA. Preclinical models for high-dose therapy. In: Armitage JO, Antman KH, eds. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 2nd ed. Baltimore, MD: Williams and Wilkins; 1995:14-42.

    • Search Google Scholar
    • Export Citation
  • 89

    Cohen MH, Creaven PJ, Fossieck BE Jr. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977;61:349-354.

  • 90

    Johnson DH, Einhorn LH, Birch R. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987;5:1731-1738.

    • Search Google Scholar
    • Export Citation
  • 91

    Ihde DC, Mulshine JL, Kramer BS. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994;12:2022-2034.

    • Search Google Scholar
    • Export Citation
  • 92

    Arriagada R, Le Chevalier T, Pignon JP. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993;329:1848-1852.

    • Search Google Scholar
    • Export Citation
  • 93

    Thatcher N, Girling DJ, Hopwood P. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 2000;18:395-404.

    • Search Google Scholar
    • Export Citation
  • 94

    Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol 1991;9:499-508.

    • Search Google Scholar
    • Export Citation
  • 95

    Crawford J, Ozer H, Stoller R. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-170.

    • Search Google Scholar
    • Export Citation
  • 96

    Genetech. Important drug warning regarding Avastin (bevacuizumab). Available at: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM153953.pdf. Accessed September 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 97

    Spigel DR, Townley PM, Waterhouse DM. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011;29:2215-2222.

    • Search Google Scholar
    • Export Citation
  • 98

    Spigel DR, Greco FA, Zubkus JD. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009;4:1555-1560.

    • Search Google Scholar
    • Export Citation
  • 99

    Horn L, Dahlberg SE, Sandler AB. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group study E3501. J Clin Oncol 2009;27:6006-6011.

    • Search Google Scholar
    • Export Citation
  • 100

    Hurria A, Kris MG. Management of lung cancer in older adults. CA Cancer J Clin 2003;53:325-341.

  • 101

    Girling DJ. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: a stopped multicentre randomised trial. Medical Research Council Lung Cancer Working Party. Lancet 1996;348:563-566.

    • Search Google Scholar
    • Export Citation
  • 102

    Souhami RL, Spiro SG, Rudd RM. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst 1997;89:577-580.

    • Search Google Scholar
    • Export Citation
  • 103

    Neubauer M, Schwartz J, Caracandas J. Results of a phase II study of weekly paclitaxel plus carboplatin in patients with extensive small-cell lung cancer with eastern cooperative oncology group performance status of 2, or age >= 70 years. J Clin Oncol 2004;22:1872-1877.

    • Search Google Scholar
    • Export Citation
  • 104

    Westeel V, Murray N, Gelmon K. New combination of the old drugs for elderly patients with small-cell lung cancer: a phase II study of the PAVE regimen. J Clin Oncol 1998;16:1940-1947.

    • Search Google Scholar
    • Export Citation
  • 105

    Okamoto H, Watanabe K, Nishiwaki Y. Phase II study of area under the plasma-concentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol 1999;17:3540-3545.

    • Search Google Scholar
    • Export Citation
  • 106

    Matsui K, Masuda N, Yana T. Carboplatin calculated with Chatelut's formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 2001;40:603-606.

    • Search Google Scholar
    • Export Citation
  • 107

    Murray N, Grafton C, Shah A. Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 1998;16:3323-3328.

    • Search Google Scholar
    • Export Citation
  • 108

    Hurwitz JL, McCoy F, Scullin P, Fennell DA. New advances in the second-line treatment of small cell lung cancer. Oncologist 2009;14:986-994.

  • 109

    Schneider BJ. Management of recurrent small cell lung cancer. J Natl Compr Canc Netw 2008;6:323-331.

  • 110

    Cheng S, Evans WK, Stys-Norman D, Shepherd FA. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol 2007;2:348-354.

    • Search Google Scholar
    • Export Citation
  • 111

    Ettinger DS. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 2001;28:27-29.

  • 112

    Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000;117:156S-162S.

  • 113

    Masters GA, Declerck L, Blanke C. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group trial 1597. J Clin Oncol 2003;21:1550-1555.

    • Search Google Scholar
    • Export Citation
  • 114

    von Pawel J, Schiller JH, Shepherd FA. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.

    • Search Google Scholar
    • Export Citation
  • 115

    O'Brien ME, Ciuleanu TE, Tsekov H. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 2006;24:5441-5447.

    • Search Google Scholar
    • Export Citation
  • 116

    Eckardt JR, von Pawel J, Pujol JL. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-2092.

    • Search Google Scholar
    • Export Citation
  • 117

    Huber RM, Reck M, Gosse H. Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer. Eur Respir J 2006;27:1183-1189.

    • Search Google Scholar
    • Export Citation
  • 118

    Shah C, Ready N, Perry M. A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. Lung Cancer 2007;57:84-88.

    • Search Google Scholar
    • Export Citation
  • 119

    Shipley DL, Hainsworth JD, Spigel DR. Topotecan: weekly intravenous (IV) schedule similar to standard 5-day IV schedule as second-line therapy for relapsed small cell lung cancer (SCLC)—a Minnie Pearl Cancer Research Network phase II trial [abstract]. J Clin Oncol 2006;24 (Suppl 18):Abstract 7083.

    • Search Google Scholar
    • Export Citation
  • 120

    Ettinger DS, Jotte R, Lorigan P. Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer. J Clin Oncol 2010;28:2598-2603.

    • Search Google Scholar
    • Export Citation
  • 121

    Inoue A, Sugawara S, Yamazaki K. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402. J Clin Oncol 2008;26:5401-5406.

    • Search Google Scholar
    • Export Citation
  • 122

    Onoda S, Masuda N, Seto T. Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301. J Clin Oncol 2006;24:5448-5453.

    • Search Google Scholar
    • Export Citation
  • 123

    Shimokawa T, Shibuya M, Kitamura K. Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer. Int J Clin Oncol 2009;14:63-69.

    • Search Google Scholar
    • Export Citation
  • 124

    Jotte R, Conkling P, Reynolds C. Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy. J Clin Oncol 2011;29:287-293.

    • Search Google Scholar
    • Export Citation
  • 125

    Simon G, Ginsberg RJ, Ruckdeschel JC. Small-cell lung cancer. Chest Surg Clin N Am 2001;11:165-188, ix.

  • 126

    Murray N, Coy P, Pater JL. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1993;11:336-344.

    • Search Google Scholar
    • Export Citation
  • 127

    Fried DB, Morris DE, Poole C. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 2004;22:4837-4845.

    • Search Google Scholar
    • Export Citation
  • 128

    Pijls-Johannesma M, De Ruysscher D, Vansteenkiste J. Timing of chest radiotherapy in patients with limited stage small cell lung cancer: a systematic review and meta-analysis of randomised controlled trials. Cancer Treat Rev 2007;33:461-473.

    • Search Google Scholar
    • Export Citation
  • 129

    Turrisi AT III, Kim K, Blum R. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340:265-271.

    • Search Google Scholar
    • Export Citation
  • 130

    Schild SE, Bonner JA, Shanahan TG. Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:943-951.

    • Search Google Scholar
    • Export Citation
  • 131

    Miller KL, Marks LB, Sibley GS. Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;56:355-359.

    • Search Google Scholar
    • Export Citation
  • 132

    Roof KS, Fidias P, Lynch TJ. Radiation dose escalation in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 2003;57:701-708.

  • 133

    Bogart JA, Herndon JE II, Lyss AP. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. Int J Radiat Oncol Biol Phys 2004;59:460-468.

    • Search Google Scholar
    • Export Citation
  • 134

    De Ruysscher D, Pijls-Johannesma M, Bentzen SM. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 2006;24:1057-1063.

    • Search Google Scholar
    • Export Citation
  • 135

    Socinski MA, Bogart JA. Limited-stage small-cell lung cancer: the current status of combined-modality therapy. J Clin Oncol 2007;25:4137-4145.

    • Search Google Scholar
    • Export Citation
  • 136

    Liengswangwong V, Bonner JA, Shaw EG. Limited-stage small-cell lung cancer: patterns of intrathoracic recurrence and the implications for thoracic radiotherapy. J Clin Oncol 1994;12:496-502.

    • Search Google Scholar
    • Export Citation
  • 137

    Kim TH, Cho KH, Pyo HR. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 2005;235:208-215.

    • Search Google Scholar
    • Export Citation
  • 138

    Rose J, Rodrigues G, Yaremko B. Systematic review of dose-volume parameters in the prediction of esophagitis in thoracic radiotherapy. Radiother Oncol 2009;91:282-287.

    • Search Google Scholar
    • Export Citation
  • 139

    Kong FM, Ritter T, Quint DJ. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus. Int J Radiat Oncol Biol Phys, in press.

    • Search Google Scholar
    • Export Citation
  • 140

    Shirvani SM, Komaki R, Heymach JV. Positron emission tomography/computed tomography-guided intensity-modulated radiotherapy for limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys, in press.

    • Search Google Scholar
    • Export Citation
  • 141

    Prescribing, recording, and reporting intensity-modulated photon-beam therapy (IMRT)(ICRU report 83). International Commission on Radiation Units & Measurements, Inc. Available at: http://www.icru.org/index.php?option=com_content&task=view&id=171. Accessed September 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 142

    Jeremic B, Shibamoto Y, Nikolic N. Role of radiation therapy in the combined-modality treatment of patients with extensive disease small-cell lung cancer: a randomized study. J Clin Oncol 1999;17:2092-2099.

    • Search Google Scholar
    • Export Citation
  • 143

    Arriagada R, Le Chevalier T, Borie F. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995;87:183-190.

    • Search Google Scholar
    • Export Citation
  • 144

    Auperin A, Arriagada R, Pignon JP. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-484.

    • Search Google Scholar
    • Export Citation
  • 145

    Patel S, Macdonald OK, Suntharalingam M. Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer. Cancer 2009;115:842-850.

    • Search Google Scholar
    • Export Citation
  • 146

    Slotman B, Faivre-Finn C, Kramer G. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med 2007;357:664-672.

  • 147

    Le Pechoux C, Dunant A, Senan S. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009;10:467-474.

    • Search Google Scholar
    • Export Citation
  • 148

    Slotman BJ, Mauer ME, Bottomley A. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms—results of an international phase III randomized controlled trial by the EORTC radiation oncology and lung cancer groups. J Clin Oncol 2009;27:78-84.

    • Search Google Scholar
    • Export Citation
  • 149

    Lutz S, Berk L, Chang E. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011;79:965-976.

    • Search Google Scholar
    • Export Citation
  • 150

    Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Onology evidence-based clinical practice guideline. Practice Radiation Oncology Web site. Available at: http://www.practicalradonc.org/article/S18798500(11)000919/abstract. Accessed September 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 151

    Lad T, Piantadosi S, Thomas P. A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 1994;106:320S-323S.

    • Search Google Scholar
    • Export Citation
  • 152

    Rostad H, Naalsund A, Jacobsen R. Small cell lung cancer in Norway. Should more patients have been offered surgical therapy? Eur J Cardiothorac Surg 2004;26:782-786.

    • Search Google Scholar
    • Export Citation
  • 153

    Inoue M, Miyoshi S, Yasumitsu T. Surgical results for small cell lung cancer based on the new TNM staging system. Thoracic Surgery Study Group of Osaka University, Osaka, Japan. Ann Thorac Surg 2000;70:1615-1619.

    • Search Google Scholar
    • Export Citation
  • 154

    Brock MV, Hooker CM, Syphard JE. Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: its time has come. J Thorac Cardiovasc Surg 2005;129:64-72.

    • Search Google Scholar
    • Export Citation
  • 155

    Lim E, Belcher E, Yap YK. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol 2008;3:1267-1271.

    • Search Google Scholar
    • Export Citation
  • 156

    Shields TW, Higgins GA Jr, Matthews MJ, Keehn RJ. Surgical resection in the management of small cell carcinoma of the lung. J Thorac Cardiovasc Surg 1982;84:481-488.

    • Search Google Scholar
    • Export Citation
  • 157

    Schreiber D, Rineer J, Weedon J. Survival outcomes with the use of surgery in limited-stage small cell lung cancer: should its role be re-evaluated? Cancer 2010;116:1350-1357.

    • Search Google Scholar
    • Export Citation
  • 158

    Inoue M, Nakagawa K, Fujiwara K. Results of preoperative mediastinoscopy for small cell lung cancer. Ann Thorac Surg 2000;70:1620-1623.

  • 159

    Shepherd FA, Evans WK, Feld R. Adjuvant chemotherapy following surgical resection for small-cell carcinoma of the lung. J Clin Oncol 1988;6:832-838.

    • Search Google Scholar
    • Export Citation
  • 160

    Tsuchiya R, Suzuki K, Ichinose Y. Phase II trial of postoperative adjuvant cisplatin and etoposide in patients with completely resected stage I-IIIa small cell lung cancer: the Japan Clinical Oncology Lung Cancer Study Group Trial (JCOG9101). J Thorac Cardiovasc Surg 2005;129:977-983.

    • Search Google Scholar
    • Export Citation
  • 161

    Johnson BE, Linnoila RI, Williams JP. Risk of second aerodigestive cancers increases in patients who survive free of small-cell lung cancer for more than 2 years. J Clin Oncol 1995;13:101-111.

    • Search Google Scholar
    • Export Citation
  • 162

    Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998;90:1335-1345.

  • 163

    Richardson GE, Tucker MA, Venzon DJ. Smoking cessation after successful treatment of small-cell lung cancer is associated with fewer smoking-related second primary cancers. Ann Intern Med 1993;119:383-390.

    • Search Google Scholar
    • Export Citation
  • 164

    Kawahara M, Ushijima S, Kamimori T. Second primary tumours in more than 2-year disease-free survivors of small-cell lung cancer in Japan: the role of smoking cessation. Br J Cancer 1998;78:409-412.

    • Search Google Scholar
    • Export Citation
  • 165

    Parsons A, Daley A, Begh R, Aveyard P. Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis. BMJ 2010;340:b5569.

    • Search Google Scholar
    • Export Citation
  • 166

    Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, eds. World Health Organization classification of tumors: pathology & genetics of tumors of the lung, pleura, thymus, and heart. World Health Organization Web site. Available at: http://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb10/index.php. Accessed September 1, 2011.

    • Search Google Scholar
    • Export Citation
  • 167

    Bajetta E, Catena L, Procopio G. Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment? Ann Oncol 2005;16:1374-1380.

    • Search Google Scholar
    • Export Citation
  • 168

    Varlotto JM, Medford-Davis LN, Recht A. Should large cell neuroendocrine lung carcinoma be classified and treated as a small cell lung cancer or with other large cell carcinomas? J Thorac Oncol 2011;6:1050-1058.

    • Search Google Scholar
    • Export Citation
  • 169

    Travis WD, Giroux DJ, Chansky K. The IASLC Lung Cancer Staging Project: proposals for the inclusion of bronchopulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer. J Thorac Oncol 2008;3:1213-1223.

    • Search Google Scholar
    • Export Citation
  • 170

    Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg 2010;89:998-1005.

  • 171

    Rea F, Rizzardi G, Zuin A. Outcome and surgical strategy in bronchial carcinoid tumors: single institution experience with 252 patients. Eur J Cardiothorac Surg 2007;31:186-191.

    • Search Google Scholar
    • Export Citation
  • 172

    Cardillo G, Sera F, Di Martino M. Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 2004;77:1781-1785.

    • Search Google Scholar
    • Export Citation
  • 173

    Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-232.

    • Search Google Scholar
    • Export Citation
  • 174

    Ekeblad S, Sundin A, Janson ET. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986-2991.

    • Search Google Scholar
    • Export Citation
  • 175

    Kulke MH, Hornick JL, Frauenhoffer C. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338-345.

    • Search Google Scholar
    • Export Citation
  • 176

    Kulke MH, Lenz HJ, Meropol NJ. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008;26:3403-3410.

  • 177

    Yao JC, Phan AT, Chang DZ. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 325 179 8
PDF Downloads 59 42 3
EPUB Downloads 0 0 0